DE69127336T2 - Hydroxymethyl(methylencyclopentyl)Purinen und Pyrimidinen - Google Patents
Hydroxymethyl(methylencyclopentyl)Purinen und PyrimidinenInfo
- Publication number
- DE69127336T2 DE69127336T2 DE69127336T DE69127336T DE69127336T2 DE 69127336 T2 DE69127336 T2 DE 69127336T2 DE 69127336 T DE69127336 T DE 69127336T DE 69127336 T DE69127336 T DE 69127336T DE 69127336 T2 DE69127336 T2 DE 69127336T2
- Authority
- DE
- Germany
- Prior art keywords
- methylenecyclopentyl
- purines
- pyrimidines
- hydroxymethyl
- chem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Tires In General (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59956890A | 1990-10-18 | 1990-10-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69127336D1 DE69127336D1 (de) | 1997-09-25 |
DE69127336T2 true DE69127336T2 (de) | 1998-01-02 |
Family
ID=24400159
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69127336T Expired - Lifetime DE69127336T2 (de) | 1990-10-18 | 1991-10-16 | Hydroxymethyl(methylencyclopentyl)Purinen und Pyrimidinen |
DE1991627336 Pending DE122006000069I1 (de) | 1990-10-18 | 1991-10-16 | Hydroxymethyl(methylencyclopentyl) Purinen und Pyrimidinen |
DE200612000069 Active DE122006000069I2 (de) | 1990-10-18 | 2006-12-22 | Hydroxymethyl(methylencyclopentyl) Purinen und pyrimidinen. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1991627336 Pending DE122006000069I1 (de) | 1990-10-18 | 1991-10-16 | Hydroxymethyl(methylencyclopentyl) Purinen und Pyrimidinen |
DE200612000069 Active DE122006000069I2 (de) | 1990-10-18 | 2006-12-22 | Hydroxymethyl(methylencyclopentyl) Purinen und pyrimidinen. |
Country Status (28)
Country | Link |
---|---|
US (1) | US5206244A (de) |
EP (1) | EP0481754B1 (de) |
JP (1) | JP2994117B2 (de) |
KR (1) | KR0160523B1 (de) |
CN (1) | CN1030916C (de) |
AT (1) | ATE157095T1 (de) |
AU (1) | AU634423B2 (de) |
BR (1) | BR1100846A (de) |
CA (1) | CA2053339C (de) |
CY (2) | CY2063B1 (de) |
DE (3) | DE69127336T2 (de) |
DK (1) | DK0481754T3 (de) |
ES (1) | ES2104673T3 (de) |
FI (1) | FI109905B (de) |
GR (1) | GR3025395T3 (de) |
HK (1) | HK1001343A1 (de) |
HU (1) | HU213207B (de) |
IE (1) | IE913451A1 (de) |
IL (1) | IL99755A (de) |
LU (1) | LU91275I2 (de) |
NL (1) | NL300241I1 (de) |
NO (2) | NO179906C (de) |
NZ (1) | NZ240053A (de) |
PL (1) | PL169403B1 (de) |
PT (1) | PT99281B (de) |
RU (1) | RU2037496C1 (de) |
SG (1) | SG70958A1 (de) |
ZA (1) | ZA917894B (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0630897A3 (de) * | 1993-06-25 | 1995-03-01 | Bristol Myers Squibb Co | 3-Hydroxy-4-hydroxymethyl-2-methylen-cyclopentyl Purine und Pyrimidine. |
US5811408A (en) * | 1994-07-12 | 1998-09-22 | Yamasa Corporation | 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides |
AU4303996A (en) * | 1994-12-19 | 1996-07-10 | Novartis Ag | 6'-substituted carbocyclic nucleosides |
GB9520363D0 (en) * | 1995-10-05 | 1995-12-06 | Chiroscience Ltd | Compounds |
WO1998009964A1 (en) * | 1996-09-03 | 1998-03-12 | Bristol-Myers Squibb Company | IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
ES2579903T3 (es) * | 1998-08-10 | 2016-08-17 | Centre National De La Recherche Scientifique (Cnrs) | Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B |
US6432966B2 (en) | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
CN1813753B (zh) * | 2000-02-29 | 2010-04-07 | 布里斯托尔-迈尔斯斯奎布公司 | 低剂量艾替开韦制剂及其应用 |
NZ520024A (en) | 2000-02-29 | 2005-03-24 | Bristol Myers Squibb Co | Low dose entecavir formulation and usein treating hepatitis B virus infection |
WO2001067772A2 (en) * | 2000-03-09 | 2001-09-13 | Videoshare, Inc. | Sharing a streaming video |
TWI275392B (en) * | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
US7153691B2 (en) * | 2002-11-13 | 2006-12-26 | G6 Science Corp. | Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents |
BRPI0317255B8 (pt) * | 2002-12-11 | 2021-05-25 | Bristol Myers Squibb Co | processo para preparar o agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona método de seu isolamento, preparação do éster e respectivos compostos |
US7511139B2 (en) * | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
TW200540175A (en) * | 2004-06-04 | 2005-12-16 | Bristol Myers Squibb Co | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
CN100379736C (zh) * | 2005-05-13 | 2008-04-09 | 上海仲夏化学有限公司 | 恩替卡韦的制备方法 |
CN1699366A (zh) * | 2005-06-03 | 2005-11-23 | 北京市典范科技有限责任公司 | 嘌呤衍生物 |
CN1907987B (zh) * | 2005-08-03 | 2010-05-05 | 江苏正大天晴药业股份有限公司 | 恩地卡韦酸加成盐及其制备方法和用途 |
US20070060599A1 (en) * | 2005-09-09 | 2007-03-15 | Dimarco John D | Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one |
CN101016299B (zh) * | 2006-02-09 | 2010-05-12 | 北京典范科技有限责任公司 | 制备嘌呤衍生物的新方法 |
CN101130542B (zh) * | 2006-08-24 | 2010-08-04 | 江苏正大天晴药业股份有限公司 | 抗病毒核苷类似物的合成方法 |
CN101210015B (zh) * | 2006-12-26 | 2010-09-22 | 上海国创医药有限公司 | 一种乙肝治疗药物恩替卡韦的制备方法 |
CN101245068A (zh) * | 2007-02-14 | 2008-08-20 | 浙江医药股份有限公司新昌制药厂 | 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途 |
CN101074217B (zh) * | 2007-04-04 | 2010-11-24 | 北京精华耀邦医药科技有限公司 | 通过制备色谱分离得到高纯度恩替卡韦关键中间体的方法 |
PT2159224E (pt) | 2007-06-18 | 2012-10-24 | Sunshine Lake Pharma Co Ltd | Tiazolil dihidropirimidinas substituídas com bromo-fenilo |
US20090076038A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched entecavir |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
EP2376514A2 (de) * | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nukleosidanaloga |
NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
MX2011006891A (es) * | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
KR101150254B1 (ko) | 2008-12-26 | 2012-06-12 | 한미사이언스 주식회사 | 신규 중간체 및 이를 활용한 엔테카비르 제조방법 |
CN101531660B (zh) * | 2009-04-14 | 2012-07-04 | 安徽贝克联合制药有限公司 | 一种恩替卡韦一水合物的工业化生产工艺 |
JP5788398B2 (ja) * | 2009-10-12 | 2015-09-30 | ハンミ・サイエンス・カンパニー・リミテッド | エンテカビルの新規な製造方法及びこれに使用される中間体 |
US9700560B2 (en) * | 2009-11-16 | 2017-07-11 | University Of Georgia Research Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
CN101759698B (zh) * | 2009-12-15 | 2012-01-18 | 上海医药集团股份有限公司 | 一种恩替卡韦的制备方法 |
US8481728B2 (en) * | 2010-02-16 | 2013-07-09 | Scinopharm Taiwan, Ltd. | Process for preparing entecavir and its intermediates |
AU2011235112B2 (en) | 2010-03-31 | 2015-07-09 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
CA2705953C (en) * | 2010-05-31 | 2018-05-01 | Alphora Research Inc. | Carbanucleoside synthesis and intermediate compounds useful therein |
EP2474548A1 (de) | 2010-12-23 | 2012-07-11 | Esteve Química, S.A. | Verfahren zur Herstellung eines antiviralen Arzneimittels und Zwischenprodukten daraus |
EP2508172A1 (de) | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Stabile und gleichförmige Formulierungen von Entecavir und Herstellungsverfahren dafür |
CN102491960A (zh) * | 2011-11-16 | 2012-06-13 | 福建广生堂药业股份有限公司 | 一种合成恩替卡韦的中间体及其制备方法和应用 |
EP2597096A1 (de) | 2011-11-24 | 2013-05-29 | Esteve Química, S.A. | Verfahren zur Herstellung von Entecavir und Zwischenprodukten dafür |
CN103304375B (zh) * | 2012-03-12 | 2017-04-12 | 浙江奥翔药业股份有限公司 | 恩替卡韦的合成中间体及其制备方法 |
AU2013257951A1 (en) | 2012-05-11 | 2015-01-22 | Akron Molecules Ag | Use of compounds for the treatment of pain |
AU2013340559B2 (en) | 2012-10-29 | 2018-03-15 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
WO2015014737A1 (en) | 2013-07-29 | 2015-02-05 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Multilayer tablet formulations comprising tenofovir and entecavir |
WO2015051900A1 (en) | 2013-10-08 | 2015-04-16 | Pharmathen S.A. | Process for the preparation of entecavir through novel intermediates |
KR101640503B1 (ko) * | 2015-04-15 | 2016-07-18 | 동방에프티엘(주) | 엔테카비르 일수화물의 개선된 제조방법 |
KR101640504B1 (ko) * | 2015-04-15 | 2016-07-18 | 동방에프티엘(주) | 엔테카비르 일수화물의 제조방법 |
WO2018092728A1 (ja) * | 2016-11-16 | 2018-05-24 | 国立研究開発法人国立国際医療研究センター | 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体 |
CN108203435B (zh) * | 2016-12-16 | 2020-09-04 | 正大天晴药业集团股份有限公司 | 一种利用Boc保护基的恩替卡韦的制备方法 |
CN106749251A (zh) * | 2017-01-17 | 2017-05-31 | 博瑞生物医药泰兴市有限公司 | 一种恩替卡韦中间体的合成与提纯方法 |
KR102197257B1 (ko) * | 2017-10-19 | 2020-12-31 | 단국대학교 천안캠퍼스 산학협력단 | 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물 |
CN109956975B (zh) * | 2017-12-22 | 2020-11-06 | 浙江柏拉阿图医药科技有限公司 | 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用 |
WO2020121123A2 (en) * | 2018-12-12 | 2020-06-18 | Janssen Biopharma, Inc. | Cyclopentyl nucleoside analogs as anti-virals |
CN113024574B (zh) * | 2019-12-25 | 2024-03-29 | 南通诺泰生物医药技术有限公司 | 一种氧杂二环己烷类化合物的制备方法 |
CN111732589B (zh) * | 2020-06-08 | 2021-07-30 | 王乔 | 一种改进的恩替卡韦中间体合成工艺以及改进的恩替卡韦合成工艺 |
CN112625041A (zh) * | 2020-12-25 | 2021-04-09 | 常州博海威医药科技股份有限公司 | 恩替卡韦的新制备方法以及中间体 |
CN115433188A (zh) * | 2022-09-29 | 2022-12-06 | 苏州东瑞制药有限公司 | 一种恩替卡韦的制备方法 |
CN115819422A (zh) * | 2022-12-13 | 2023-03-21 | 淄博矿业集团有限责任公司 | 恩替卡韦中间体制备新工艺方法及分析方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN164556B (de) * | 1986-03-06 | 1989-04-08 | Takeda Chemical Industries Ltd | |
US5063233A (en) * | 1986-11-14 | 1991-11-05 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists |
KR910008800B1 (ko) * | 1987-03-19 | 1991-10-21 | 야마사 쇼오유 가부시끼가이샤 | 2'-알킬리덴 피리미딘 누클레오시드 유도체, 그 제조법, 및 그 용도 |
US4997925A (en) * | 1987-08-26 | 1991-03-05 | Merrell Dow Pharmaceuticals Inc. | 5'-deoxy-5',5'-dihalo adenosines and purine analogues |
NZ225906A (en) * | 1987-08-26 | 1990-10-26 | Merrell Dow Pharma | Aristeromycin/adenosine derivatives and pharmaceutical compositions |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
EP0566162B1 (de) * | 1988-08-25 | 1997-06-11 | Yoshitomi Pharmaceutical Industries, Ltd. | 2'-Methylidenpyrimidinnukleosidverbindungen, ihre Verwendung und Verfahren zu ihrer Herstellung |
HU204843B (en) * | 1988-09-27 | 1992-02-28 | Merrell Dow Pharma | Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same |
GB8916478D0 (en) * | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
US5064961A (en) * | 1989-12-18 | 1991-11-12 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutane nucleoside |
US5057630A (en) * | 1990-04-06 | 1991-10-15 | Glaxo Inc. | Synthesis of cyclopentene derivatives |
-
1991
- 1991-09-20 US US07/763,033 patent/US5206244A/en not_active Expired - Lifetime
- 1991-10-01 NZ NZ240053A patent/NZ240053A/xx not_active IP Right Cessation
- 1991-10-01 IE IE345191A patent/IE913451A1/en active Protection Beyond IP Right Term
- 1991-10-02 ZA ZA917894A patent/ZA917894B/xx unknown
- 1991-10-04 AU AU85598/91A patent/AU634423B2/en not_active Expired
- 1991-10-11 CA CA002053339A patent/CA2053339C/en not_active Expired - Lifetime
- 1991-10-15 IL IL9975591A patent/IL99755A/en not_active IP Right Cessation
- 1991-10-16 DE DE69127336T patent/DE69127336T2/de not_active Expired - Lifetime
- 1991-10-16 DK DK91309525.3T patent/DK0481754T3/da active
- 1991-10-16 AT AT91309525T patent/ATE157095T1/de active
- 1991-10-16 EP EP91309525A patent/EP0481754B1/de not_active Expired - Lifetime
- 1991-10-16 ES ES91309525T patent/ES2104673T3/es not_active Expired - Lifetime
- 1991-10-16 SG SG1996002080A patent/SG70958A1/en unknown
- 1991-10-16 DE DE1991627336 patent/DE122006000069I1/de active Pending
- 1991-10-17 RU SU915001946A patent/RU2037496C1/ru active Protection Beyond IP Right Term
- 1991-10-17 KR KR1019910018259A patent/KR0160523B1/ko not_active IP Right Cessation
- 1991-10-17 NO NO914089A patent/NO179906C/no not_active IP Right Cessation
- 1991-10-17 HU HU913283A patent/HU213207B/hu active Protection Beyond IP Right Term
- 1991-10-18 CN CN91110831A patent/CN1030916C/zh not_active Expired - Lifetime
- 1991-10-18 JP JP3271121A patent/JP2994117B2/ja not_active Expired - Lifetime
- 1991-10-18 PL PL91292101A patent/PL169403B1/pl unknown
- 1991-10-18 FI FI914928A patent/FI109905B/fi active Protection Beyond IP Right Term
- 1991-10-18 PT PT99281A patent/PT99281B/pt not_active IP Right Cessation
-
1997
- 1997-05-12 BR BR1100846-6A patent/BR1100846A/pt active IP Right Grant
- 1997-11-17 GR GR970403039T patent/GR3025395T3/el unknown
-
1998
- 1998-01-19 HK HK98100422A patent/HK1001343A1/xx not_active IP Right Cessation
- 1998-06-12 CY CY9802063A patent/CY2063B1/xx unknown
-
2006
- 2006-08-30 LU LU91275C patent/LU91275I2/fr unknown
- 2006-09-21 NL NL300241C patent/NL300241I1/nl unknown
- 2006-12-05 NO NO2006018C patent/NO2006018I2/no unknown
- 2006-12-22 DE DE200612000069 patent/DE122006000069I2/de active Active
-
2014
- 2014-09-29 CY CY2006008C patent/CY2006008I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE157095T1 (de) | Hydroxymethyl(methylencyclopentyl)purinen und pyrimidinen | |
ES2056096T3 (es) | Purinil-ciclobutanos. | |
NO920210L (no) | Antivirale pyrimidinnukleosider | |
IL118367A0 (en) | Heteroaroyl derivatives | |
ES2093051T3 (es) | Purinil- y pirimidil-tetrahidrofuranos. | |
ES2055211T3 (es) | Purinil- y pirimidinil-tetrahidrofuranos. | |
ATE138382T1 (de) | Antitumor- und antivirale-verbindung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R071 | Expiry of right |
Free format text: PRODUCT NAME: ENTECAVIR UND PHARMAZEUTISCH VERTRAEGLICHE SALZE UND HYDRATE; REGISTRATION NO/DATE: EU/1/06/343/001-005 20060626 Spc suppl protection certif: 122006000069 Filing date: 20061222 Expiry date: 20111017 Extension date: 20170416 |